MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jacl.2026.09.016

Медицинская библиотека · Journal of clinical lipidology · 2026

NST-1024 for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 28-day clinical trial.

Kastelein John Jp, Skjæret Tore, Jeannin Sophie, Beyusen Robin, Fraser David A, Maki Kevin C

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

NST-1024 is a semisynthetic eicosapentaenoic acid (EPA) derivative developed with the aim of achieving more potent triglyceride (TG) lowering effects as compared to unmodified EPA in conjunction with improved glycemic control.

OBJECTIVE

To evaluate the efficacy and safety of oral NST-1024 400 mg twice daily in patients with severe hypertriglyceridemia (sHTG) in a phase 2 proof-of-concept study.

METHODS

After a 2 to 4-week run-in period, men and women with TG levels ≥500 mg/dL and ≤ 2000 mg/dL were randomized to double-blind treatment with placebo or NST-1024 for 4 weeks. The primary endpoint was the % change from baseline in TGs at 4 weeks.

RESULTS

The evaluable population for efficacy analysis comprised 44 participants (NST-1024 [n = 23], placebo [n = 21]). At baseline, median TG (interquartile limits) levels were 730 (599-862) and 723 (611-863) mg/dL in the NST-1024 and placebo groups, respectively, and the median % changes after 4 weeks of treatment were -35.9% and -9.1%, respectively, a placebo-corrected change of -31.8% (P = .01). Treatment with NST-1024 significantly increased high-density lipoprotein cholesterol vs placebo (P = .04) with no significant difference between groups for non-high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or apolipoprotein B. Fasting plasma glucose (least square [LS] mean difference -22 mg/dL, P = .01) and C-peptide (LS mean difference -398 pmol/L, P < .01) were both significantly reduced in NST-1024 treated patients vs placebo. NST-1024 was generally well tolerated.

CONCLUSION

Treatment with oral NST-1024 400 mg twice daily significantly reduced TGs in patients with sHTG in conjunction with improvements in glycemic control. This trial was registered at www.

CLINICALTRIALS: gov as NCT05889156.

Для цитирования: Kastelein John Jp, Skjæret Tore, Jeannin Sophie, Beyusen Robin, Fraser David A, Maki Kevin C. NST-1024 for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 28-day clinical trial.. Journal of clinical lipidology. 2026. DOI: 10.1016/j.jacl.2026.09.016.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.